Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "early lung health"

Impact: Collaboration

On this Research Impact page, we list stories helping demonstrate how we collaborate with other leaders, innovators, communities, and international stakeholders to ensure excellent research results. The better our results, the better the chances of research making a real difference.

Funding the future of our research

Dr Anthony Bosco, Professor Steve Stick, Professor Andrew Whitehouse, Dr Raelene Endersby and Dr Luke Garratt know how fortunate they are to have

News & Events

The Impact of Poverty - interview with Steve Zubrick

Growing up poor is about more than just the size of your bank account. Read the new CoLab Impact of Poverty Evidence Report.

Phage WA Artificial Intelligence Team

Our team uses AI to quickly analyse large amounts of genetic data to help discover alternate medications and improve existing treatments.

News & Events

We're back at Scitech this July!

Everything you need to know to book tickets to our upcoming school holiday workshops in July held at Scitech!

News & Events

School holiday workshops at Scitech

Everything you need to know to book tickets to our upcoming school holiday workshops in April held at Scitech!

News & Events

20-year MAVRIC study celebrates recruitment of its 1000th participant

The MAVRIC (Mechanisms of Acute Viral Respiratory Infection in Children) study recently celebrated the recruitment of the 1000th participant to the study, eight-year-old Sullivan Strahan.

Vaccine and immunisation trials pivotal in the fight against potentially deadly virus

As a leading research site in Australia, the Wesfarmers Centre of Vaccines and Infectious Diseases played an instrumental role in the global effort to develop a world-first RSV immunisation for young babies.

Research

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.

Research

TESTOV Pneumo

Christopher Elke Jennifer Tom Blyth Seppanen Kent Snelling MBBS (Hons) DCH FRACP FRCPA PhD BSc PhD RN BMBS DTMH GDipClinEpid PhD FRACP Centre Head,